Venus Concept (VERO)

[Triple nickle]

Building up steam

[Triple nickle]

It went positive yesterday

[Triple nickle]

Buy rating to 2.20

[Triple nickle]

Adding

[81vette]

finally, accumulation started,seller/debt might be done,its moving better now

[81vette]

Shares outstanding 67m,volume today 78m,lots of bills paid today,future looking good with many other news worthy products in pipeline

[81vette]

$29.5m traded today(record high),follow the money,monthly trend so far

[81vette]

gap filled,rsi bouncing off oversold,loading zone now

[81vette]

300Xs ave volume,at least 10x pps should follow

[81vette]

zero borrow,no shares to short>12.83% 0.00% 0 2022-12-21 10:45:03
12.83% 0.00% 0 2022-12-21 10:30:03
12.83% 0.00% 0 2022-12-21 10:15:03
12.83% 0.00% 0 2022-12-21 10:00:03
12.83% 0.00% 0 2022-12-21 09:45:03
12.83% 0.00% 0 2022-12-21 09:30:03
12.83% 0.00% 0 2022-12-21 09:15:04
12.83% 0.00% 0 2022-12-21 09:00:03
12.83% 0.00% 0 2022-12-21 08:45:04
12.83% 0.00% 0 2022-12-21 08:30:03
12.83% 0.00% 0 2022-12-21 08:15:03
12.83% -8.51% 75000 2022-12-21 08:00:03
12.83% -8.51% 850000 2022-12-20 17:45:03
12.83% -8.51% 850000 2022-12-20 17:30:04
12.83% -8.51% 850000 2022-12-20 17:15:03
12.83% -8.51% 850000 2022-12-20 17:00:04
12.83% -8.51% 850000 2022-12-20 16:45:04

[81vette]

FDA news this big should run many days

[subslover]

Venus Concept Receives 510(k) Clearance for Use of its AI.ME™ Next Generation Robotic Technology for Fractional Skin Resurfacing
December 21 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its AI.ME next generation robotic technology for fractional skin resurfacing.

“We are very pleased to receive the first FDA regulatory clearance for our non-surgical robotic technology platform, AI.ME, and believe it showcases Venus Concept’s ongoing investment in technology, innovation, and clinical research towards robotics applications in the field of medical aesthetics,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “AI.ME is a first-of-its-kind robotic platform offering physicians minimally-invasive treatments for high-demand procedures requiring fractional skin resurfacing. We see AI.ME as a versatile platform and we will continue to develop the platform to provide innovative solutions in various areas of medical aesthetics, starting with fractional skin resurfacing. The AI.ME technology will be critical to maximizing the synergy between our well-established medical aesthetic business and our pioneering robotics business driven by a robust R&D pipeline developed by our team in San Jose. This 510(k) clearance brings us one step closer to our goal of commercializing AI.ME in the U.S., and we look forward to introducing our first AI.ME systems with Venus Concept’s leading physician partners in 2023.”

The AI.ME robotic system utilizes an advanced visualization system, machine vision, and Artificial Intelligence algorithms to target the dermis in a pre-planned selective, and predictable manner. It uses a smart array of micro-coring hollow punches to precisely core and excise micro-skin fractions at a precise depth to remove up to 10% of skin in the treatment area, leading to collagen deposition and fractional skin resurfacing of the treated area.

“Integrating the advancements of robotics into the area of minimally-invasive aesthetic procedures is very promising,” said Girish (Gilly) Munavalli, MD, MHS, FACMS board-certified dermatologist and advisor to Venus Concept. “This new technology may become a real game-changer in the area of medical aesthetics, offering a new level of consistency, predictability, and visualization which will differentiate it from existing energy-based solutions. We had the privilege to participate in the early clinical studies of AI.ME and it is clear that the advancements that its robotic technology presents to our practice can go far beyond fractional skin resurfacing. I’m encouraged to see some true innovation in the area of minimally-invasive aesthetic treatments and I’m looking forward to seeing the technology evolve to produce consistent transformational results.”

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 16 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Cautionary Statement Regarding Forward-Looking Statements

[reena969]

..64 = 100%

[reena969]

FDA news $$$

[DK11]

I thought this stock was about to show promise, maybe not

[DK11]

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001409269/000143774922026907/vero20220930_10q.htm
Is this stock going to be de-listed from Nasdaq read page 58.???

[DK11]

This is super tight it has to go. Ready to explode

[INFINITI]

Super thin here$$$

[INFINITI]

Should be an awsome week $$$$

[INFINITI]

Looking good here I’m in $$$$$

[SantaZar]

#DDAmanda Chart on: $VERO :

You can scan for these before they run.



#DDAmanda is still the best way to find #WinningStocks before they run.
Contact/Text: 760 702-2009

What the Fact (Factor) Column is:

The Factor is a proprietary indicator used for scanning in #DDAmanda.

It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).

SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.

That's significant, and many times indicates that a run in the stock is coming.

Z

[lecorb]

First rating to update target price today!
Marie Thibault
BTIG
4.5 Stars
target
$7.00
ranking
Buy
analystAction
Reiterated
date
14 hours ago
TDAmeritrade Inc.

[lecorb]

Venus Concept Stock Trades Higher After Lifting FY21 Sales Outlook
11:19 am ET August 13, 2021 (Benzinga) Print
Venus Concept Inc's (NASDAQ: VERO) Q2 sales increased 52% Y/Y to $25.8 million, beating the consensus of $24.26 million.
The increase by product category was driven by a 71% increase in lease revenue, a 29% increase in systems revenue, an 86% increase in products revenue, and a 5% increase in services revenue.
The gross margin improved to 72.5% from 70.0%, primarily driven by higher sales of Venus consumables and improved revenue mix of system sales sold under our subscription program, tracing to Venus Bliss.
Operating income increased 117% Y/Y to $1.5 million compared to a loss of $(8.8) million a year ago.
EPS of $0.01 improved from a loss of $(0.39) and ahead of analyst estimate loss of $(0.12).
FY21 Guidance: Venus expects sales of $102 million - $107 million, representing a 31% - 37% Y/Y increase, better than the Wall Street estimate of $103.24 million.
Prior sales estimate were $100 million - $105 million, +28% to 35%, Y/Y.
Price Action: VERO shares are up 1.91% at $2.13 during the market session on the last check Friday.

[lecorb]

NSTITUTIONAL OWNERSHIP CHANGES (13F FILINGS) FOR VENUS CONCEPT (NASDAQ:VERO)
Institutional Ownership Percentage: 43.04%

8/13/2021 Vanguard Group Inc. 1,011,657 $3.15M 0.0% +3.4% 1.871%
8/12/2021 Dimensional Fund Advisors LP 116,052 $0.36M 0.0% +29.8% 0.215%
8/12/2021 Essex Investment Management Co. LLC 733,425 $2.28M 0.3% +47.2% 1.356%
8/12/2021 Ergoteles LLC 107,516 $0.33M 0.0% N/A 0.199%
8/11/2021 Bank of New York Mellon Corp 36,048 $0.11M 0.0% -57.4% 0.067%
8/11/2021 Deutsche Bank AG 59,500 $0.19M 0.0% +396.7% 0.110%
8/11/2021 Susquehanna Fundamental Investments LLC 13,000 $40K 0.0% N/A 0.024%
8/3/2021 Oppenheimer & Co. Inc. 15,500 $48K 0.0% N/A 0.029%

[makinezmoney]

$VERO: My bad...... $25.8MIlly in QUARTERLY REVS

And Venus Williams ?????????


WOW


Cheap here at $2.10 now

Confidence is Venus Williams' secret to looking and feeling her best. In this master video, watch as Venus explains all the reasons why she loves Venus Bliss™! https://t.co/37CHKiwSDd

— Venus Aesthetic Intelligence (@Venus_A_I) August 3, 2021

GO $VERO

[lecorb]

When they double their target price, possibly the monday more than one compulsive short seller will cry a lot

Marie Thibault
BTIG
StarStarStarStarStar
target
$7.00
ranking
Buy
analystAction
Reiterated
date
2 months ago


Anthony Vendetti
Maxim Group
StarStarStarStarStar
target
$6.00
ranking
Buy
analystAction
Reiterated
date
3 months ago


Suraj Kalia
Oppenheimer
StarStarStarStarStar
target
$4.00
ranking
Buy
analystAction
Maintained
date
3 months ago

[makinezmoney]

$VERO: Solid Earnings report......... $2.58Milly quarterly revs


BRIEF-Venus Concept Announces Second Quarter 2021 Financial Results Increases Fiscal Year 2021 Revenue Guidance
7:14 AM ET 8/13/21 | Reuters
BRIEF-Venus Concept Announces Second Quarter 2021 Financial Results Increases Fiscal Year 2021 Revenue Guidance
Aug 13 (Reuters) - Venus Concept Inc:

* VENUS CONCEPT ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS; INCREASES FISCAL YEAR 2021 REVENUE GUIDANCE

* Q2 REVENUE $25.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $24.3 MILLION

* SEES FY 2021 REVENUE UP ABOUT 31 TO 37 PERCENT

* SEES FY 2021 REVENUE $102 MILLION TO $107 MILLION

* FY2021 REVENUE VIEW $103.2 MILLION -- REFINITIV IBES DATA

* Q2 EARNINGS PER SHARE $0.01

* Q2 EARNINGS PER SHARE VIEW $-0.12 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:



GO $VERO

[OR Nurse]

CRNA. You don't think you can sneak into VERO headquarters and snap a few photos and see if you see anything can you? Perhaps post them here. Asking for a friend. lol

[OR Nurse]

CRNA. You don't think you can sneak into VERO headquarters and snap a few photos and see if you see anything can you? Perhaps post them here. Asking for a friend.

[Adrock]

HAIR OUT THE ENOS pal!!

[BigT82]

Growing BIG after hours pal!

To da mooooon!!

[Adrock]

SCOOOOOOOOOOOOP DAT HAIR GROWTH!

[BigT82]

Nice pop! Let’s goooo!

Huge Monday news coming!

Merger Monday!?

[Adrock]

Scooooooooooooooop Em!!!

[BigT82]

Moving on up! Let’s gooo!

[CRNA]

Isn’t anybody excited about zaring. Scoping out the company for Medtronic for a buyout

[Roadtojourney]

Ofcouse imo

[Roadtojourney]

This was higher few days back even before this fluff news

[Roadtojourney]

Makes no sense volume was more yesterday AH

[saigai]

volume is awesome...

[Roadtojourney]

Why is it not flying?? The news is good the stock is good too??

[Roadtojourney]

And down it goes

[boston127]

Starts out slow every AM.

I have noticed this trend. Thus, I pick up an additional 100-200 shares in the AM and do not get flustered with momentary ups and downs. The trend is our friend.

[boston127]

Venus Concept started at outperform

with $15 stock price target at Oppenheimer (1-10-2020). They are a very credible investment firm. Think I will hang in here for awhile.

[boston127]

Nice move up today.

I doubled up my holdings this AM, just as it hit the high of the day. ): That's OK. This is a keeper. The products are great.

Fiscal Year 2020 Revenue Guidance:

Total revenue for the twelve months ended December 31, 2020 is expected to be in the range of $134.0 million to $140.0 million. The Company’s fiscal year 2020 revenue guidance range represents projected growth of approximately 9% to 13% year-over-year as compared to the preliminary total revenue range, on a pro-forma basis, of $122.6 million to $123.5 million for the twelve months ended December 31, 2019.